Sugi Predict

Sugi Predict / Compounds / SCHEMBL1923416

SCHEMBL1923416

SCHEMBL1923416

NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.56
▸ DPP8 Q6V1X1 2/20 0.49
▸ DPP9 Q86TI2 2/20 0.49
▸ DPP7 Q9UHL4 2/20 0.49
▸ FOLH1 Q04609 1/20 0.47
▸ GNAI3 P08754 1/20 0.45
▸ GNAO1 P09471 1/20 0.45
▸ GNAI1 P63096 1/20 0.45
▸ TGFBR1 P36897 1/20 0.44
▸ DPP4 P27487 1/20 0.43
▸ MMP2 P08253 2/20 0.43
▸ RNPEP Q9H4A4 1/20 0.42
▸ NMT1 P30419 4/20 0.41
▸ NMT2 O60551 3/20 0.41
▸ CPB2 Q96IY4 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ MME P08473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28264447 1.00 GSR (0.56) GSRDPP8DPP9DPP7FOLH1
SCHEMBL24141455 0.97 GSR (0.53) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29465874 0.97 GSR (0.53) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30943792 0.97 GSR (0.53) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30277638 0.95 GSR (0.51) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30039547 0.95 GSR (0.51) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29943324 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30581338 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29630424 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29592035 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377110-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2025-08-05 — — US claimed
WO-2025067293-A1 HELICASE AND USE THEREOF 北京齐碳科技有限公司 2025-04-03 — — WO claimed
CN-119709689-A Helicase and application thereof 北京齐碳科技有限公司 2025-03-28 — — CN claimed
WO-2025064654-A1 TRUNCATED TISSUE PLASMINOGEN ACTIVATOR PROTEINS AND USE THEREOF THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-03-27 — — WO claimed
WO-2024132726-A1 SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE UNIWERSYTET GDANSKI (PL) 2024-06-27 — — WO claimed
CN-110732018-B Preparation method of tuna meat ACE inhibitory peptide chewable tablets 浙江海洋大学 2023-04-07 — — CN claimed
US-20230084521-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2023-03-16 — — US claimed
EP-4013769-A2 ZINC ACTIVATED THYMULIN AND METHODS OF PREPARATION AND ADMINISTRATION Cytolyf Therapeutics LLC (US) 2022-06-22 — — EP claimed
US-20220105050-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-04-07 — — US claimed
CN-102731629-B Antibacterial peptide and application thereof CHANGCHUN PROTELIGHT PHARMACEUTICAL & BIOTECHNOLOGY CO LTD 2015-05-20 — — CN claimed
US-12624002-B2 Dimers for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-05-12 — — US disclosed
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 — — US disclosed
US-12595233-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-07 — — US disclosed
US-20260091097-A1 COMBINATION TREATMENT REGIMES FOR TREATING CANCER BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) 2026-04-02 — — US disclosed
US-20260070894-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-03-12 — — US disclosed
US-20030060408-A1 Metal-binding compounds and uses therefor AMPIO PHARMACEUTICALS, INC. 2003-03-27 — — US disclosed
CN-1390231-A Metal-binding compound and use thereof DMI BIOLOG SCIENCE CO (US) 2003-01-08 — — CN disclosed
WO-2002064620-A2 METAL-BINDING COMPOUNDS AND USES THEREFOR DMI BIOSCIENCES, INC. (US) 2002-08-22 — — WO disclosed
EP-1220870-A1 METAL-BINDING COMPOUNDS AND USES THEREFOR DMI Biosciences, Inc. (US) 2002-07-10 — — EP disclosed
WO-2001025265-A1 METAL-BINDING COMPOUNDS AND USES THEREFOR DMI BIOSCIENCES, INC. (US) 2001-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091097-A1 COMBINATION TREATMENT REGIMES FOR TREATING CANCER IL2, IFNG, ICOS GSR 4364/4885DPP8 3462/4885DPP9 3415/4885
US-12624002-B2 Dimers for use in synthesis of peptidomimetics GLUL, ARGLU1, ASNS GSR 1732/4885DPP8 1069/4885DPP9 426/4885
US-20260070894-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS NPR1, NGLY1, DDAH1 GSR 4811/4885DPP8 380/4885DPP9 184/4885
US-12595233-B2 Thiosemicarbazates and uses thereof TST, THRB, HSPB1 GSR 3336/4885DPP8 46/4885DPP9 14/4885
US-12377110-B2 Fospropofol methods and compositions FOS, FOSB, PFAS GSR 4624/4885DPP8 2001/4885DPP9 1994/4885
US-20030060408-A1 Metal-binding compounds and uses therefor SLC39A11, ROS1, NOX4 GSR 32/4885DPP8 2456/4885DPP9 3295/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT GSR 1842/4885DPP8 183/4885DPP9 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback